why choose us

Course: Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic

CME Credits: 1.00

Released: 2021-05-21

The novel SARS-CoV-2 virus has caused more than 118 million cases of COVID-19 and more than 2.6 million deaths worldwide. To evaluate the use of potential therapeutic options—including dexamethasone, remdesivir, enoxaparin, heparin, colchicine, hydrocortisone, tocilizumab, azithromycin, hydroxychloroquine, and medication classes of angiotensin-2 converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)—we measured daily and overall use percentages over the course of 2020 for hospitalized patients.


Educational Objective
To identify the key insights or developments described in this article


View Full Course